SR Pharma Establishes GMP Production with Partners for RNAi Therapeutic Product
News Jun 16, 2006
SR Pharma plc has announced that its operating subsidiary Atugen AG, has established collaborations with Genzyme, BioSpring and OctoPlus to manufacture and formulate its lead RNAi therapeutic product Atu027 to GMP standards.
Atu027 is a siRNA based anti-cancer drug, that is on track to enter initial clinical trials in the first half of 2007.
In combination, these suppliers will provide product for the forthcoming pharmacokinetic and toxicology studies as well as the planned clinical studies.
Completion of the pre-clinical trials of Atu027 later this year will provide the basis for the Company to progress third party out-licensing deals for the general RNAi delivery system (AtuPLEX) used in Atu027 as well as permitting SR Pharma to start the first phase I clinical trial of Atu027 during the first half of 2007.
Iain Ross, Executive Chairman of SR Pharma, stated, "Atugen is rapidly moving forward towards testing the clinical applications of Atu027 and towards delivering some potential commercial out-licensing applications for its drug delivery system AtuPLEX."
"Consultation with the German regulatory agency for drug approval (BfArM) will be held shortly to define the final steps before entering the clinic with Atu027."
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE
Faulty Gene Leads to Alcohol-Induced Heart FailureNews
A faulty gene interacts with alcohol to accelerate heart failure in susceptible patients, a study suggests. This dangerous interaction can occur even when only moderate amounts of alcohol have been consumed.READ MORE
Genetic Diversity Helps Protect Against DiseaseNews
Why do populations have genetic diversity when 'Survival of the Fittest' suggests that only one gene pool should thrive? It's a question that is hard to answer experimentally. A new study looking at evolutionary change in real time in tiny fungal parasites may provide a solution.